The Food and Drug Administration is moving to dismantle one of the most persistent barriers to affordable medicine in the United States: the slow approval of generic versions of biological drugs. These complex therapies, developed from living cells rather than chemicals, have long been both the pharmaceutical industry’s most prized
Breaking the biologic bottleneck
By shortening timelines and lowering costs, regulators aim to reshape incentives that have historically favored brand-name drugmakers.